​

VistaGen Therapeutics (VTGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VTGN Stock Forecast

VistaGen Therapeutics (VTGN) stock forecast, based on 3 Wall Street analysts, predicts a 12-month average price target of $6.00, with a high of $6.00 and a low of $6.00. This represents a 109.79% increase from the last price of $2.86.

High: $6 Avg: $6 Low: $6 Last Closed Price: $2.86

VTGN Stock Rating

VistaGen Therapeutics stock's rating consensus is Buy, based on 3 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (66.67%), 1 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 3 1 2 0 Strong Sell Sell Hold Buy Strong Buy

VTGN Forecast vs Benchmarks

TypeNameUpside
StockVistaGen Therapeutics109.79%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$2.86$2.86$2.86
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2513---4
Dec, 2413---4
Nov, 2413---4
Oct, 2433---6
Sep, 2433---6
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 22, 2022Andrew TsaiJefferies$6.00$4.3836.99%109.79%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Aug 07, 2023Maxim GroupBuyupgrade
Apr 26, 2022Zacks Investment ResearchHolddowngrade
Feb 18, 2021JefferiesBuyinitialise

Financial Forecast

EPS Forecast

$-15 $-11 $-7 $-3 $1 $5 Mar 21 Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-6.25$-7.24$-8.51$-1.52-----
Avg Forecast$-6.38$-6.68$-8.40$-1.60$-1.83$-1.90$-2.05$-1.01$1.23
High Forecast$-13.49$-14.12$-14.87$-1.78$-1.88$-2.85$-2.44$-1.79$0.73
Low Forecast$-2.05$-2.14$-4.96$-1.50$-1.77$-1.34$-1.62$-0.60$2.18
Surprise %-2.04%8.38%1.31%-5.00%-----

Revenue Forecast

$-50M $50M $150M $250M $350M $450M Mar 21 Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$1.09M$1.11M$-227.30K$1.06M-----
Avg Forecast$877.30K$1.32M$-403.00K$1.07M$689.33K$632.65K$6.94M$69.85M$260.38M
High Forecast$419.24K$632.93K$-641.76K$849.62K$268.57K$433.32K$4.75M$47.84M$178.34M
Low Forecast$1.63M$2.46M$-276.03K$1.21M$1.34M$1.01M$11.05M$111.24M$414.64M
Surprise %24.19%-16.28%-43.60%-0.26%-----

Net Income Forecast

$-300M $-230M $-160M $-90M $-20M $50M Mar 21 Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-17.93M$-47.76M$-59.25M$-29.36M-----
Avg Forecast$-123.38M$-129.19M$-162.58M$-32.07M$-35.37M$-40.61M$-39.29M$-19.55M$23.81M
High Forecast$-261.07M$-273.36M$-287.80M$-34.49M$-36.42M$-55.23M$-47.22M$-34.60M$14.06M
Low Forecast$-39.64M$-41.50M$-95.99M$-28.94M$-34.31M$-25.98M$-31.35M$-11.54M$42.14M
Surprise %-85.46%-63.03%-63.56%-8.45%-----

VTGN Forecast FAQ

Is VistaGen Therapeutics stock a buy?

VistaGen Therapeutics stock has a consensus rating of Buy, based on 3 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that VistaGen Therapeutics is a favorable investment for most analysts.

What is VistaGen Therapeutics's price target?

VistaGen Therapeutics's price target, set by 3 Wall Street analysts, averages $6 over the next 12 months. The price target range spans from $6 at the low end to $6 at the high end, suggesting a potential 109.79% change from the previous close price of $2.86.

How does VistaGen Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

VistaGen Therapeutics stock forecast shows a 109.79% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for VistaGen Therapeutics over the past three months?

  • January 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is VistaGen Therapeutics’s EPS forecast?

VistaGen Therapeutics's average annual EPS forecast for its fiscal year ending in March is -1.83 for 2025, a 20.39% increase from the reported $-1.52 in 2024. The prediction for 2026 is $-1.9, $-2.05 for 2027, $-1.01 for 2028, and $1.23 for 2029.

What is VistaGen Therapeutics’s revenue forecast?

VistaGen Therapeutics's average annual revenue forecast for its fiscal year ending in March is $689.33K for 2025, a -35.21% decrease from the reported $1.06M in 2024. The forecast for 2026 is $632.65K, $6.94M for 2027, $69.85M for 2028, and $260.38M for 2029.

What is VistaGen Therapeutics’s net income forecast?

For its fiscal year ending in March, VistaGen Therapeutics's average annual net income forecast is $-35.366M for 2025, reflecting an 20.46% increase from the reported $-29.358M in 2024. The projection for 2026 is $-40.606M, $-39.29M for 2027, $-19.548M for 2028, and $23.81M for 2029.